Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A new study shows that a specific test can help find which people with Barrett's esophagus have a higher risk of esophageal cancer. Barrett's esophagus is a condition associated with abnormal changes (called dysplasia) in the cells lining the esophagus. These changes are not cancerous, but they can become cancerous over time as the cells become more abnormal. Although all people with Barrett's esophagus are at risk for esophageal cancer, there has been no good way to find out who is more likely to develop cancer.
Researchers found that the targeted therapy regorafenib lengthens the lives of patients with metastatic colorectal cancer (colorectal cancer that has spread outside the colon and rectum) and slows the growth of the cancer. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
Researchers used a new blood test that correctly identified the presence of early-stage pancreatic cancer in two-thirds of patients participating in this study. The test detects a specialized protein, called PAM-4, in a person's blood. PAM-4 is a tumor marker, which is a substance found at higher than normal levels in the blood, urine, and body tissues of people with cancer. Developing a test for pancreatic cancer is important because patients have a better chance of survival when pancreatic cancer is found early. Currently, there is no test approved by the U.S. Food and Drug Administration to detect and diagnose pancreatic cancer early.
In a new analysis of results from a previous study, researchers found that certain factors predict whether an advanced neuroendocrine tumor will worsen. Based on these factors, the drug everolimus (Afinitor) combined with octreotide (Sandostatin) may be a more effective treatment than previously thought. A neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is a cross between hormone-producing cells and nerve cells.